Abstract: A flush-mount valve and vent assemblies including the same are described. A flush-mount valve may include a valve mount and a valve barrier which are coupled to the underside of a structure forming part of a liquid-impermeable container. The flush-mount valve is arranged to control the flow of fluid(s) across a fluid passage in the structure and is mounted to the structure so as to remain fully within the interior of the container.

Abstract: Technologies and implementations for a defibrillator electrode having communicative capabilities are generally disclosed.

Abstract: Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.

Abstract: Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.

Abstract: This disclosure provides compositions, pharmaceutical preparations, and uses of polyribonucleotides encoding one or more immunogenic polypeptides. In particular, this disclosure features circular polyribonucleotide encoding one or more immunogenic polypeptides.

Abstract: The invention is directed towards an electrochemically active cathode material for a battery. The electrochemically active cathode material includes a non-stoichiometric beta-delithiated layered nickel oxide. The non-stoichiometric beta-delithiated layered nickel oxide has a chemical formula. The chemical formula is LixAyNi1+a?zMzO2·nH2O where x is from about 0.02 to about 0.20; y is from about 0.03 to about 0.20; a is from about 0.02 to about 0.2; z is from about 0 to about 0.2; and n is from about 0 to about 1. Within the chemical formula, A is an alkali metal. The alkali metal includes potassium, rubidium, cesium, and any combination thereof. Within the chemical formula, M comprises an alkaline earth metal, a transition metal, a non-transition metal, and any combination thereof.

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

Abstract: The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyI)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yI]-1-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.

Abstract: The invention is directed towards an electrochemically active cathode material. The electrochemically active cathode includes beta-delithiated layered nickel oxide and an electrochemically active cathode material selected from the group consisting of manganese oxide, manganese dioxide, electrolytic manganese dioxide (EMD), chemical manganese dioxide (CMD), high power electrolytic manganese dioxide (HP EMD), lambda manganese dioxide, gamma manganese dioxide, beta manganese dioxide, and mixtures thereof. The beta-delithiated layered nickel oxide has an X-ray diffraction pattern. The X-ray diffraction pattern of the beta-delithiated layered nickel oxide includes a first peak from about 14.9°2? to about 16.0°2?; a second peak from about 21.3°2? to about 22.7°2?; a third peak from about 37.1°2? to about 37.4°2?; a fourth peak from about 43.2°2? to about 44.0°2?; a fifth peak from about 59.6°2? to about 60.6°2?; and a sixth peak from about 65.4°2? to about 65.9°2?.

Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.

Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.

Abstract: The invention is directed towards an electrochemically active cathode material for a battery. The electrochemically active cathode material includes a non-stoichiometric beta-delithiated layered nickel oxide. The non-stoichiometric beta-delithiated layered nickel oxide has a chemical formula. The chemical formula is LixAyNi1+a?zMzO2·nH2O where x is from about 0.02 to about 0.20; y is from about 0.03 to about 0.20; a is from about 0.02 to about 0.2; z is from about 0 to about 0.2; and n is from about 0 to about 1. Within the chemical formula, A is an alkali metal. The alkali metal includes potassium, rubidium, cesium, and any combination thereof. Within the chemical formula, M comprises an alkaline earth metal, a transition metal, a non-transition metal, and any combination thereof.

Abstract: One example embodiment is adapted for use in facilitating collection and transport of memory devices, e.g., drives, motherboards, etc., e.g., for the purposes of subsequent destruction. The example embodiment has an outer bin, also called a garage or outer enclosure, within which is placed an inner bin with wheels. Once closed and locked, the outer bin has a door that can be opened so drives or other memory devices can be inserted. The drives then fall into the inner bin and, once sufficiently filled, the inner bin be easily wheeled out from the outer bin. The inner bin has its own locking lid that is secured when transporting the inner bin with the drives, e.g., to a destruction facility or area. Other features are provided as described below. Enhanced synergistic security features include use of multi-point locking latches to secure doors and lids, metal construction of the bins, and so on. The bins are sized to facilitate efficient collection and transport of potentially sensitive data center media.

Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.

Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.

Abstract: The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

Abstract: The disclosure provides compositions and methods for generating polyclonal antibodies, for example, using circular polyribonucleotides and non-human animals having humanized immune systems.

Abstract: Provided are electrochemically active particles suitable for use as an active material in a cathode of a lithium ion electrochemical cell that include: a plurality of crystallites including a first composition comprising lithium, nickel, and oxygen; and a grain boundary between adjacent crystallites of the plurality of crystallites and comprising a second composition comprising lithium, nickel, and oxygen; wherein the grain boundary has a higher electrochemical affinity for lithium than the crystallites. The higher electrochemical affinity for Li leads to increased Li retention in the grain boundaries during or at charge relative to the bulk crystallites and stabilizes the structure of the grain boundaries and crystallites for improved cycling stability with no appreciable loss in capacity.

Abstract: This disclosure provides compositions, pharmaceutical preparations, and uses of polyribonucleotides encoding one or more immunogenic polypeptides. In particular, this disclosure features circular polyribonucleotide encoding one or more immunogenic polypeptides.

Abstract: The disclosure provides compositions and methods comprising circular polyribonucleotides comprising a sequence encoding a coronavirus antigen, and compositions and methods comprising linear polyribonucleotides comprising a sequence encoding a coronavirus antigen. Compositions and methods are provided that are related to generating polyclonal antibodies, for example, using the disclosed circular polyribonucleotides or the disclosed linear polyribonucleotides.